JP2022503733A - 口腔粘膜炎を治療するための方法および組成物 - Google Patents

口腔粘膜炎を治療するための方法および組成物 Download PDF

Info

Publication number
JP2022503733A
JP2022503733A JP2021515005A JP2021515005A JP2022503733A JP 2022503733 A JP2022503733 A JP 2022503733A JP 2021515005 A JP2021515005 A JP 2021515005A JP 2021515005 A JP2021515005 A JP 2021515005A JP 2022503733 A JP2022503733 A JP 2022503733A
Authority
JP
Japan
Prior art keywords
present disclosure
pharmaceutical composition
bisphosphocin
weight
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021515005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022503733A5 (enExample
Inventor
ケイツ、スティーブン、エイ．
パーキンソン、スティーブン
オコナー、パトリック、シー．
Original Assignee
レイクウッド アメディックス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レイクウッド アメディックス、インコーポレイテッド filed Critical レイクウッド アメディックス、インコーポレイテッド
Publication of JP2022503733A publication Critical patent/JP2022503733A/ja
Publication of JP2022503733A5 publication Critical patent/JP2022503733A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
JP2021515005A 2018-10-17 2019-10-17 口腔粘膜炎を治療するための方法および組成物 Pending JP2022503733A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746943P 2018-10-17 2018-10-17
US62/746,943 2018-10-17
PCT/US2019/056772 WO2020081839A1 (en) 2018-10-17 2019-10-17 Methods and compositions for treating oral mucositis

Publications (2)

Publication Number Publication Date
JP2022503733A true JP2022503733A (ja) 2022-01-12
JP2022503733A5 JP2022503733A5 (enExample) 2022-10-26

Family

ID=70281364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515005A Pending JP2022503733A (ja) 2018-10-17 2019-10-17 口腔粘膜炎を治療するための方法および組成物

Country Status (12)

Country Link
US (2) US11123357B2 (enExample)
EP (1) EP3866810A4 (enExample)
JP (1) JP2022503733A (enExample)
KR (1) KR20210075968A (enExample)
CN (1) CN112839662A (enExample)
AU (1) AU2019361999A1 (enExample)
BR (1) BR112021006954A2 (enExample)
CA (1) CA3116157A1 (enExample)
IL (1) IL282100A (enExample)
MX (1) MX2021004396A (enExample)
SG (1) SG11202103180QA (enExample)
WO (1) WO2020081839A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795192B2 (en) * 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US20240245717A1 (en) * 2022-12-14 2024-07-25 Lakewood Amedex, Inc. Antiviral compounds, compositions, and uses thereof
WO2025179296A1 (en) * 2024-02-22 2025-08-28 Lakewood Amedex, Inc. Crystalline forms of nu-3 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508280A (ja) * 2006-10-25 2010-03-18 オリゴス イーティーシー． インコーポレイテッド 抗微生物性および抗ウイルス性化合物ならびにそれらの使用のための方法
WO2017165673A1 (en) * 2016-03-23 2017-09-28 University Of Utah Research Foundation Spinal traction device

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US5167950A (en) 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
EP0748203A1 (en) 1994-03-11 1996-12-18 The Procter & Gamble Company LOW pH, HYDROLYTICALLY STABLE, COSMETIC COMPOSITIONS CONTAINING ACIDIC ACTIVES
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
US6946118B1 (en) * 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
WO2003032909A2 (en) 2001-10-18 2003-04-24 Ilex Products, Inc. Methods of treating skin with diphosphonate derivatives
US20030236217A1 (en) * 2002-05-21 2003-12-25 Shalwitz Robert A. Treatment of mucositis
CN1687100A (zh) * 2005-04-05 2005-10-26 奥林格斯技术有限公司 修饰性核苷酸及其用途
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US8884000B2 (en) 2010-02-17 2014-11-11 Albert Einstein College Of Medicine Of Yeshiva University Saporin-L1 inhibitors and uses thereof
EP2601205A2 (en) 2010-08-03 2013-06-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Guanine nucleotide derivatives for treating bacterial infections
AU2013264820A1 (en) * 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
AU2015338969B2 (en) 2014-10-30 2020-08-27 Biomet Manufacturing, Llc Methods of preventing surgical site infections
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
KR102684529B1 (ko) * 2017-03-10 2024-07-12 레이크우드 아메덱스, 인크. 항미생물 화합물, 조성물, 및 그의 용도
KR20260035292A (ko) 2017-06-12 2026-03-12 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508280A (ja) * 2006-10-25 2010-03-18 オリゴス イーティーシー． インコーポレイテッド 抗微生物性および抗ウイルス性化合物ならびにそれらの使用のための方法
WO2017165673A1 (en) * 2016-03-23 2017-09-28 University Of Utah Research Foundation Spinal traction device

Also Published As

Publication number Publication date
WO2020081839A1 (en) 2020-04-23
CN112839662A (zh) 2021-05-25
MX2021004396A (es) 2021-06-04
AU2019361999A1 (en) 2021-02-25
CA3116157A1 (en) 2020-04-23
US20200121708A1 (en) 2020-04-23
IL282100A (en) 2021-05-31
US20210393666A1 (en) 2021-12-23
US11123357B2 (en) 2021-09-21
SG11202103180QA (en) 2021-05-28
EP3866810A1 (en) 2021-08-25
KR20210075968A (ko) 2021-06-23
BR112021006954A2 (pt) 2021-07-20
EP3866810A4 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
AU2023285791B2 (en) Antimicrobial compounds, compositions, and uses thereof
US20210393666A1 (en) Methods and compositions for treating oral mucositis
US20240391944A1 (en) Antimicrobial compounds, compositions, and uses thereof
EP3417862A1 (en) Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs
WO2024226869A1 (en) Substituted pyrimidinedione compounds, compositions, and uses thereof
US11377468B2 (en) Antimicrobial compounds, compositions, and uses thereof
JP7149991B2 (ja) 発泡剤を含む抗微生物組成物
US12030908B2 (en) Antimicrobial compounds, compositions, and uses thereof
JP2026515887A (ja) 置換ピリミジノンおよびアザピリミジノン化合物、組成物、ならびにそれらの使用
HK40018480A (en) Antimicrobial compounds, compositions, and uses thereof
HK40018480B (en) Antimicrobial compounds, compositions, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221017

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230601